Publications by authors named "Juliana Au Anzai"
Article Synopsis
- Lecanemab is a monoclonal antibody designed to target amyloid beta in Alzheimer's disease, with its short half-life influenced by plasma protein interactions.
- The study investigated how lecanemab binds to plasma proteins, with a focus on its biosimilar, using techniques like ELISA and Western blotting.
- Results showed that fibrinogen is a binding partner for lecanemab, potentially affecting the availability of free antibodies in the bloodstream and highlighting the importance of plasma protein binding in therapeutic antibody treatment for neurodegenerative diseases.
